Healthcare provider profile · identity verified

Suk Won Park, MD

Family Practice · FONTANA, CA · NPI 1720136500

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	538	224
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	459	121
Amlodipine Besylate	Amlodipine Besylate	363	150
Lisinopril	Lisinopril	338	123
Losartan Potassium	Losartan Potassium	281	107
Levothyroxine Sodium	Levothyroxine Sodium	258	85
Rosuvastatin Calcium	Rosuvastatin Calcium	234	92
Omeprazole	Omeprazole	227	86
Metformin Hcl	Metformin Hcl	213	81
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	207	35
Simvastatin	Simvastatin	177	61
Metoprolol Tartrate	Metoprolol Tartrate	173	65
Pantoprazole Sodium	Pantoprazole Sodium	167	56
Atenolol	Atenolol	163	56
Potassium Chloride	Potassium Chloride	160	65
Trazodone Hcl	Trazodone Hcl	145	56
Albuterol Sulfate Hfa	Albuterol Sulfate	143	81
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	141	57
Ozempic	Semaglutide	138	23
Pradaxa	Dabigatran Etexilate Mesylate	138	38
Tramadol Hcl	Tramadol Hcl	135	31
Ibuprofen	Ibuprofen	134	58
Hydrochlorothiazide	Hydrochlorothiazide	126	51
Glipizide	Glipizide	111	45
Gabapentin	Gabapentin	106	39
Alendronate Sodium	Alendronate Sodium	103	42
Tamsulosin Hcl	Tamsulosin Hcl	102	41
Sertraline Hcl	Sertraline Hcl	99	38
Alprazolam	Alprazolam	94	17
Furosemide	Furosemide	88	48
Lorazepam	Lorazepam	72	16
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	69	28
Terazosin Hcl	Terazosin Hcl	69	29
Morphine Sulfate Er	Morphine Sulfate	63	13
Meloxicam	Meloxicam	60	23
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	58	19
Clopidogrel	Clopidogrel Bisulfate	57	23
Humulin N Kwikpen	Insulin Nph Human Isophane	57	19
Cephalexin	Cephalexin	56	41
Famotidine	Famotidine	56	20
Bisoprolol Fumarate	Bisoprolol Fumarate	54	20
Nitroglycerin	Nitroglycerin	53	17
Spironolactone	Spironolactone	52	18
Wixela Inhub	Fluticasone Propion/Salmeterol	52	21
Prednisone	Prednisone	50	31
Carvedilol	Carvedilol	48	14
Metformin Hcl Er	Metformin Hcl	47	20
Acetaminophen-Codeine	Acetaminophen With Codeine	44	11
Fluticasone Propionate	Fluticasone Propionate	42	15
Humulin N	Insulin Nph Human Isophane	42	16
Montelukast Sodium	Montelukast Sodium	42	16
Lactulose	Lactulose	41	13
Propranolol Hcl	Propranolol Hcl	41	11
Pravastatin Sodium	Pravastatin Sodium	40	13
Fenofibrate	Fenofibrate	38	16
Lovastatin	Lovastatin	38	15
Hydralazine Hcl	Hydralazine Hcl	37	15
Azithromycin	Azithromycin	36	24
Fluoxetine Hcl	Fluoxetine Hcl	36	15
Ezetimibe	Ezetimibe	34	13
Sumatriptan Succinate	Sumatriptan Succinate	34	suppressed
Finasteride	Finasteride	32	13
Donepezil Hcl	Donepezil Hcl	31	11
Naproxen	Naproxen	30	16
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	28	28
Chlorthalidone	Chlorthalidone	28	11
Spiriva Respimat	Tiotropium Bromide	28	suppressed
Eliquis	Apixaban	27	suppressed
Jardiance	Empagliflozin	27	13
Breyna	Budesonide/Formoterol Fumarate	26	suppressed
Ondansetron Odt	Ondansetron	26	17
Temazepam	Temazepam	26	suppressed
Allopurinol	Allopurinol	25	13
Duloxetine Hcl	Duloxetine Hcl	25	15
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	18
Oxybutynin Chloride Er	Oxybutynin Chloride	24	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	23	23
Hydrocortisone	Hydrocortisone	23	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	23	suppressed
Ketoconazole	Ketoconazole	23	12
Metoprolol Succinate	Metoprolol Succinate	22	suppressed
Nifedipine Er	Nifedipine	21	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	21	suppressed
Acyclovir	Acyclovir	20	suppressed
Alvesco	Ciclesonide	20	suppressed
Nabumetone	Nabumetone	20	suppressed
Buspirone Hcl	Buspirone Hcl	19	suppressed
Colchicine	Colchicine	19	suppressed
Methocarbamol	Methocarbamol	19	suppressed
Topiramate	Topiramate	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Humulin R	Insulin Regular, Human	18	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	16	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	16	15
Estradiol	Estradiol	16	suppressed
Memantine Hcl	Memantine Hcl	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Azelastine Hcl	Azelastine Hcl	15	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Promethazine Hcl	Promethazine Hcl	15	suppressed
Amiodarone Hcl	Amiodarone Hcl	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Trospium Chloride	Trospium Chloride	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Nystatin	Nystatin	13	suppressed
Baclofen	Baclofen	12	suppressed
Betamethasone Valerate	Betamethasone Valerate	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	suppressed
Felodipine Er	Felodipine	12	suppressed
Cefuroxime	Cefuroxime Axetil	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	11	suppressed
Fluocinonide	Fluocinonide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error